Galecto (NASDAQ: GLTO) to use January 2026 presentation at J.P. Morgan event

Rhea-AI Filing Summary

Galecto, Inc. filed a current report to let investors know it plans to meet with securities analysts, investors and others in connection with the 44th Annual J.P. Morgan Healthcare Conference beginning on January 12, 2026. During these meetings, the company intends to use a January 2026 corporate slide presentation, which is included as Exhibit 99.1. The company states that this material is being furnished under Regulation FD, meaning it is not considered filed for liability purposes and will only be incorporated into other SEC documents if specifically referenced.

0001800315false00018003152026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

GALECTO, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39655		37-1957007
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

75 State Street, Suite 100

Boston, MA 02109

(Address of principal executive offices, including zip code)

(+45) 70 70 52 10

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trade Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value per share		GLTO		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 – Regulation FD Disclosure.

Galecto, Inc. (the “Company”) intends to conduct meetings with securities analysts, investors and others in connection with the 44th Annual J.P. Morgan Healthcare Conference beginning on January 12, 2026. As part of these meetings, the Company intends to utilize the corporate slide presentation furnished with this Current Report on Form 8-K as Exhibit 99.1.

The information in this Item 7.01, including Exhibit 99.1 hereto, is being furnished, not filed, pursuant to Regulation FD. Accordingly, The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Corporate Presentation (January 2026)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Galecto, Inc.
Date: January 12, 2026				By:		/s/ Sherwin Sattarzadeh
						Sherwin Sattarzadeh
						Chief Operating Officer

FAQ

What did Galecto, Inc. (GLTO) report in this Form 8-K?

Galecto, Inc. reported that it plans to hold meetings with securities analysts, investors and others in connection with the 44th Annual J.P. Morgan Healthcare Conference beginning on January 12, 2026, and that it will use a January 2026 corporate presentation as part of these meetings.

What is Exhibit 99.1 in Galecto, Inc.’s (GLTO) 8-K filing?

Exhibit 99.1 is Galecto, Inc.’s Corporate Presentation (January 2026), which the company intends to use in meetings with analysts, investors and others at the 44th Annual J.P. Morgan Healthcare Conference.

How is the Galecto, Inc. (GLTO) corporate presentation treated under SEC rules?

Galecto, Inc. states that the information in Item 7.01 and Exhibit 99.1 is being furnished, not filed under Regulation FD, so it is not deemed filed under Section 18 of the Exchange Act and is only incorporated into other SEC filings if specifically referenced.

Which SEC item does Galecto, Inc. (GLTO) use for this disclosure?

The company uses Item 7.01 – Regulation FD Disclosure to describe its planned meetings at the 44th Annual J.P. Morgan Healthcare Conference and its use of the January 2026 corporate presentation.

Who signed the Galecto, Inc. (GLTO) Form 8-K related to the J.P. Morgan conference?

The Form 8-K was signed on behalf of Galecto, Inc. by Sherwin Sattarzadeh, who is identified as the company’s Chief Operating Officer.

Does this Galecto, Inc. (GLTO) 8-K include financial statements?

No. Under Item 9.01, the company lists only Exhibit 99.1, the January 2026 corporate presentation, and Exhibit 104, the cover page interactive data file, without additional financial statements.